CAS: 20737-42-2; 3-Oxo-3,4-Dihydropyrazine-2-Carboxylic Acid
该化合物是一种环状环状环状的环状有机化合物,其特点是存在一个碳球酸功能组和一个可促进其反应和潜在生物活动的氯酮组;二氢正对子素结构表明,它含有一种饱和的丙烯衍生物,可参与各种化学反应,包括氧化和凝聚; 箱式酸组增强了其在极地溶剂中的溶解性,能够促进与生物系统的互动,使其对药用化学感兴趣;此外,该化合物还可能显示出抗微生物酸或抗氧化剂活动等特性,尽管具体的生物影响将取决于进一步的经验研究;其独特的结构特征和功能组使其成为有机合成和药物应用研究的宝贵化合物.
- 相似结构搜索
- 产品信息参考
;; - InChIKey: FJZRUSFQHBBTCC-UHFFFAOYSA-N
- InChI=1S/C5H4N2O3/c8-4-3(5(9)10)6-1-2-7-4/h1-2H,(H,7,8)(H,9,10)
- 计算化学: 氢键受体数3.0氢键供体数2.0可旋转键数1.0
相似化合物
77168-83-3 13924-99-7 81411-78-1物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
CAS号5424-01-1 3-氨基吡嗪-2-羧酸 | CAS号487-21-8 2,4-二羟基蝶啶 | CAS号55321-99-8 3-羟基吡嗪-2-酰胺 | CAS号27825-20-3 3-羟基-2-吡嗪甲酸甲酯 | CAS号27398-39-6 2-氯吡嗪-3-羧酸 | CAS号27825-21-4 3-氯吡嗪-2-羧酸甲酯 | CAS号55321-99-8 3-羟基吡嗪-2-酰胺 | CAS号6270-63-9 羟基吡嗪 | CAS号90361-99-2 2-氯-3-吡嗪羰酰氯 | CAS号63012-78-2 5H-Thiazolo[3,2... | CAS号63012-89-5 3-chloro-N-(4,5...合成工艺路线路线简述
📜3-氨基吡嗪-2-羧酸甲酯置于硫酸,水,Sodium Hydroxide体系中,用 甲醇,水 用作溶剂,化学反应 2.41H,反应生成3-羟基-2-吡嗪甲酸
参考文献: Alpha 7 Nicotinic Acetylcholine Allosteric Modulators,Their Derivatives And Uses Thereof[fr] Modulateurs Allostériques De Récepteurs Nicotiniques De L'Acétylcholine De Type Alpha 7,Leurs Dérivés Et Utilisations
标题: Alpha 7 Nicotinic Acetylcholine Allosteric Modulators,Their Derivatives And Uses Thereof[fr] Modulateurs Allostériques De Récepteurs Nicotiniques De L'Acétylcholine De Type Alpha 7,Leurs Dérivés Et Utilisations
摘要:本申请涉及公式i所代表的化合物,这些化合物是al Nachrs的新型正向变构调节剂.该申请还披露了通过给哺乳动物施加公式i化合物的有效量来增强乙酰胆碱对al Nachrs的作用以治疗对增强乙酰胆碱作用有反应的疾病.
海关参考信息
- 2905110000-甲醇
2912110000-甲醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-1551403-B1
优先权日:2002-10-10
标 题 :5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
发明人：SEMPLE GRAEME; AVERBUJ CLAUDIA; SKINNER PHILIP; GHARBAOUI TAWFIK; SHIN YOUNG-JUN
权利人:ARENA PHARM INC
摘要:The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R2 is H, halogen, C1-12 alkyl or C1-12 haloalkyl; and R3 is C3-6 cycloalkyl, C1-12 alkyl, C1-12 haloalkyl, C3-6 cycloalkyl-C1-4-alkylene, aryl-C1-4-alkylene or heteroaryl-C1-4-alkylene, wherein said aryl-C1-4-alkylene and heteroaryl-C1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.
专利号:CN-114539169-A
优先权日:2020-11-18
标题 :A kind of pyrazine ring synthesis method containing substituent
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2016).
摘要:Sato, N., Science of Synthesis, (2004) 16, 799.
📝 需求与反馈
尽可能描述清楚需求与问题信息
